Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Global coagulation assays in transgender women on oral and transdermal estradiol therapy|
|Citation:||Journal of Clinical Endocrinology and Metabolism, 2020; 105(7):e2369-e2377|
|Publisher:||Oxford University Press|
|Hui Yin Lim, Shalem Y. Leemaqz, Niloufar Torkamani, Mathis Grossmann, Jeffrey D. Zajac, Harshal Nandurkar, Prahlad Ho, and Ada S. Cheung|
|Abstract:||Context: The thrombotic effects of estradiol therapy in transgender women are unclear. Global coagulation assays (GCA) may be better measures of hemostatic function compared with standard coagulation tests. Objective: To assess the GCA profiles of transgender women in comparison to cisgender controls and to compare how GCA differ between routes of estradiol therapy in transgender women. Design: Cross-sectional case-control study. Setting: General community. Participants: Transgender women, cisgender male and cisgender female controls. Main Outcome Measures: Citrated blood samples were analyzed for (i) whole blood thromboelastography (TEG®5000), (ii) platelet-poor plasma thrombin generation (calibrated automated thrombogram); and (iii) platelet-poor plasma fibrin generation (overall hemostatic potential assay). Mean difference (95% confidence intervals) between groups are presented. Results: Twenty-six transgender women (16 oral estradiol, 10 transdermal estradiol) were compared with 98 cisgender women and 55 cisgender men. There were no differences in serum estradiol concentration (P = 0.929) and duration of therapy (P = 0.496) between formulations. Transgender women demonstrated hypercoagulable parameters on both thromboelastography (maximum amplitude + 6.94 mm (3.55, 10.33); P < 0.001) and thrombin generation (endogenous thrombin potential + 192.62 nM.min (38.33, 326.91); P = 0.009; peak thrombin + 38.10 nM (2.27, 73.94); P = 0.034) but had increased overall fibrinolytic potential (+4.89% (0.52, 9.25); P = 0.024) compared with cisgender men. No significant changes were observed relative to cisgender women. Route of estradiol delivery or duration of use did not influence the GCA parameters. Conclusion: Transgender women on estradiol therapy demonstrated hypercoagulable GCA parameters compared with cisgender men with a shift towards cisgender female parameters. Route of estradiol delivery did not influence the GCA parameters.|
|Keywords:||Global coagulation assays; coagulation; estrogen; thrombosis; transgender|
|Rights:||© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: email@example.com|
|Appears in Collections:||Aurora harvest 8|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.